| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 12 | 2019 | 191 | 1.400 |
Why?
|
| Hypokalemia | 2 | 2024 | 13 | 1.000 |
Why?
|
| Catheters, Indwelling | 3 | 2015 | 67 | 0.940 |
Why?
|
| Glucagon-Like Peptides | 1 | 2025 | 8 | 0.910 |
Why?
|
| Paralysis, Hyperkalemic Periodic | 1 | 2025 | 8 | 0.910 |
Why?
|
| Muscular Diseases | 1 | 2025 | 51 | 0.880 |
Why?
|
| Mineralocorticoid Excess Syndrome, Apparent | 1 | 2024 | 2 | 0.870 |
Why?
|
| Glycyrrhizic Acid | 1 | 2024 | 3 | 0.870 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2022 | 5 | 0.850 |
Why?
|
| Acidosis, Lactic | 2 | 2023 | 11 | 0.840 |
Why?
|
| Diabetic Nephropathies | 3 | 2022 | 38 | 0.800 |
Why?
|
| Nephrologists | 2 | 2020 | 7 | 0.790 |
Why?
|
| Nephrology | 2 | 2020 | 16 | 0.780 |
Why?
|
| Metformin | 1 | 2023 | 76 | 0.750 |
Why?
|
| Catheter-Related Infections | 4 | 2019 | 43 | 0.750 |
Why?
|
| Fellowships and Scholarships | 2 | 2020 | 106 | 0.720 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2021 | 8 | 0.690 |
Why?
|
| Glomerulonephritis | 1 | 2021 | 32 | 0.670 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 14 | 0.630 |
Why?
|
| Advisory Committees | 1 | 2020 | 111 | 0.620 |
Why?
|
| Vascular Access Devices | 2 | 2019 | 15 | 0.600 |
Why?
|
| Hypertension | 2 | 2024 | 610 | 0.590 |
Why?
|
| Kidney Transplantation | 6 | 2012 | 327 | 0.560 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2017 | 1 | 0.550 |
Why?
|
| Societies, Medical | 1 | 2020 | 401 | 0.540 |
Why?
|
| Human Growth Hormone | 1 | 2017 | 19 | 0.540 |
Why?
|
| Growth Disorders | 1 | 2017 | 30 | 0.530 |
Why?
|
| Body Height | 1 | 2017 | 66 | 0.530 |
Why?
|
| Melanoma | 1 | 2021 | 332 | 0.530 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 554 | 0.520 |
Why?
|
| Gentamicins | 2 | 2014 | 25 | 0.510 |
Why?
|
| Humans | 67 | 2025 | 64969 | 0.480 |
Why?
|
| Gastric Bypass | 2 | 2013 | 69 | 0.460 |
Why?
|
| Silicones | 1 | 2015 | 14 | 0.460 |
Why?
|
| Kidney | 8 | 2013 | 453 | 0.460 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 30 | 0.450 |
Why?
|
| Kidney Failure, Chronic | 6 | 2019 | 196 | 0.450 |
Why?
|
| Diuretics | 3 | 2011 | 58 | 0.430 |
Why?
|
| Citrates | 1 | 2014 | 18 | 0.430 |
Why?
|
| Machine Learning | 3 | 2021 | 194 | 0.430 |
Why?
|
| Central Venous Catheters | 1 | 2014 | 17 | 0.420 |
Why?
|
| Anti-Bacterial Agents | 4 | 2015 | 806 | 0.420 |
Why?
|
| Male | 36 | 2025 | 30921 | 0.420 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 730 | 0.410 |
Why?
|
| Calcium Oxalate | 2 | 2013 | 13 | 0.400 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 84 | 0.400 |
Why?
|
| Hepatitis B Antibodies | 1 | 2012 | 9 | 0.390 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2012 | 18 | 0.390 |
Why?
|
| Hepatitis B Vaccines | 1 | 2012 | 16 | 0.380 |
Why?
|
| Acute Kidney Injury | 3 | 2017 | 142 | 0.380 |
Why?
|
| Living Donors | 1 | 2012 | 79 | 0.370 |
Why?
|
| Middle Aged | 28 | 2025 | 18166 | 0.370 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 864 | 0.370 |
Why?
|
| Ethanol | 1 | 2015 | 330 | 0.360 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 105 | 0.360 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 94 | 0.360 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2011 | 3 | 0.350 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 26 | 0.340 |
Why?
|
| Nephritis, Interstitial | 3 | 2005 | 15 | 0.330 |
Why?
|
| Hypoglycemic Agents | 2 | 2023 | 226 | 0.300 |
Why?
|
| Aldosterone | 3 | 2024 | 18 | 0.290 |
Why?
|
| Personnel Selection | 2 | 2020 | 57 | 0.280 |
Why?
|
| Terbutaline | 2 | 1998 | 2 | 0.280 |
Why?
|
| Arteriovenous Shunt, Surgical | 4 | 2019 | 43 | 0.270 |
Why?
|
| Heart Failure | 2 | 2017 | 942 | 0.270 |
Why?
|
| Female | 33 | 2024 | 33868 | 0.260 |
Why?
|
| Potassium | 5 | 2011 | 98 | 0.250 |
Why?
|
| Sarcoidosis | 2 | 2005 | 35 | 0.250 |
Why?
|
| Creatinine | 6 | 2017 | 135 | 0.250 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 46 | 0.230 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2025 | 30 | 0.220 |
Why?
|
| Immunosorbent Techniques | 1 | 2004 | 9 | 0.220 |
Why?
|
| Adult | 21 | 2023 | 17267 | 0.220 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 2004 | 7 | 0.220 |
Why?
|
| Hyperkalemia | 2 | 2004 | 20 | 0.220 |
Why?
|
| Staphylococcal Protein A | 1 | 2004 | 5 | 0.220 |
Why?
|
| Alkalosis | 1 | 2024 | 2 | 0.220 |
Why?
|
| Glycyrrhiza | 1 | 2024 | 2 | 0.220 |
Why?
|
| Mitomycin | 1 | 2004 | 27 | 0.220 |
Why?
|
| Antigen-Antibody Complex | 1 | 2004 | 52 | 0.220 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2004 | 38 | 0.220 |
Why?
|
| Peritoneal Dialysis | 3 | 2011 | 13 | 0.210 |
Why?
|
| Duodenitis | 1 | 2003 | 1 | 0.210 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 30 | 0.210 |
Why?
|
| Methylamines | 1 | 2023 | 11 | 0.210 |
Why?
|
| Carbon Dioxide | 2 | 2023 | 85 | 0.200 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 68 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2011 | 234 | 0.200 |
Why?
|
| Aged | 17 | 2024 | 14880 | 0.200 |
Why?
|
| Lactic Acid | 1 | 2023 | 75 | 0.200 |
Why?
|
| Hydrocortisone | 1 | 2024 | 193 | 0.190 |
Why?
|
| Pancreatitis | 1 | 2003 | 97 | 0.190 |
Why?
|
| Kidney Diseases | 5 | 2011 | 178 | 0.190 |
Why?
|
| Electrolytes | 3 | 1998 | 26 | 0.190 |
Why?
|
| Dietary Supplements | 1 | 2024 | 234 | 0.180 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 203 | 0.180 |
Why?
|
| Anti-Infective Agents | 2 | 2019 | 150 | 0.180 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 30 | 0.170 |
Why?
|
| Alanine | 1 | 2021 | 50 | 0.170 |
Why?
|
| Efficiency | 1 | 2020 | 40 | 0.160 |
Why?
|
| Kidney Glomerulus | 1 | 2000 | 23 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2021 | 180 | 0.160 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2020 | 40 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 184 | 0.160 |
Why?
|
| Acidosis | 2 | 1993 | 27 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 3 | 2011 | 120 | 0.160 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2021 | 213 | 0.160 |
Why?
|
| Lupus Nephritis | 1 | 2000 | 37 | 0.150 |
Why?
|
| Forecasting | 1 | 2020 | 231 | 0.150 |
Why?
|
| Tissue Donors | 1 | 2000 | 147 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 210 | 0.150 |
Why?
|
| Hand Disinfection | 1 | 2019 | 18 | 0.150 |
Why?
|
| Aspirin | 2 | 2011 | 172 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 369 | 0.140 |
Why?
|
| Infant, Premature | 4 | 2007 | 192 | 0.140 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2009 | 60 | 0.140 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 34 | 0.140 |
Why?
|
| Faculty, Medical | 1 | 2020 | 201 | 0.140 |
Why?
|
| Osteopontin | 2 | 2009 | 21 | 0.140 |
Why?
|
| Biomarkers | 2 | 2022 | 1469 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 155 | 0.140 |
Why?
|
| Myocardial Contraction | 1 | 1998 | 89 | 0.140 |
Why?
|
| Thrombosis | 3 | 2011 | 205 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2021 | 325 | 0.140 |
Why?
|
| Oxalates | 3 | 1997 | 19 | 0.140 |
Why?
|
| Immunosuppressive Agents | 3 | 2011 | 380 | 0.140 |
Why?
|
| Treatment Outcome | 6 | 2017 | 5779 | 0.140 |
Why?
|
| Job Application | 1 | 2017 | 7 | 0.130 |
Why?
|
| Ritodrine | 1 | 1997 | 1 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 207 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 220 | 0.130 |
Why?
|
| Obstetric Labor, Premature | 1 | 1997 | 31 | 0.130 |
Why?
|
| Hemodynamics | 1 | 1998 | 252 | 0.130 |
Why?
|
| Proteinuria | 3 | 2005 | 43 | 0.130 |
Why?
|
| Heparin | 2 | 2015 | 118 | 0.120 |
Why?
|
| Risk Factors | 7 | 2017 | 5400 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 877 | 0.120 |
Why?
|
| Allopurinol | 2 | 2001 | 15 | 0.120 |
Why?
|
| Time Factors | 5 | 2017 | 3759 | 0.120 |
Why?
|
| Vascular Patency | 3 | 2011 | 134 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2015 | 79 | 0.110 |
Why?
|
| Elastic Modulus | 1 | 2015 | 39 | 0.110 |
Why?
|
| Stress, Mechanical | 1 | 2015 | 113 | 0.110 |
Why?
|
| Furosemide | 3 | 2011 | 19 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2015 | 78 | 0.110 |
Why?
|
| Materials Testing | 1 | 2015 | 87 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2015 | 220 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 350 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 5586 | 0.100 |
Why?
|
| Drug Hypersensitivity | 1 | 1994 | 28 | 0.100 |
Why?
|
| Hepatitis | 1 | 1994 | 58 | 0.100 |
Why?
|
| Asthma | 1 | 1998 | 472 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2020 | 3315 | 0.100 |
Why?
|
| Receptors, Calcium-Sensing | 1 | 2013 | 6 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2020 | 6817 | 0.100 |
Why?
|
| Hyperoxaluria | 1 | 2013 | 10 | 0.100 |
Why?
|
| Treatment Refusal | 2 | 2007 | 56 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 1994 | 172 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2015 | 520 | 0.100 |
Why?
|
| Dipyridamole | 2 | 2011 | 17 | 0.100 |
Why?
|
| Injections, Intradermal | 1 | 2012 | 11 | 0.100 |
Why?
|
| Kidney Calculi | 1 | 2013 | 34 | 0.100 |
Why?
|
| Acetylcysteine | 1 | 2012 | 25 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 445 | 0.100 |
Why?
|
| Immunization, Secondary | 1 | 2012 | 52 | 0.090 |
Why?
|
| Infant | 1 | 2017 | 1690 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 384 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2017 | 2090 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 141 | 0.090 |
Why?
|
| Adolescent | 5 | 2021 | 6311 | 0.090 |
Why?
|
| Nephrolithiasis | 1 | 2011 | 8 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 2060 | 0.090 |
Why?
|
| Ultrafiltration | 1 | 2011 | 10 | 0.090 |
Why?
|
| Serum Albumin | 1 | 1992 | 48 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 12 | 0.090 |
Why?
|
| Kidney Papillary Necrosis | 1 | 1991 | 1 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 176 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 2494 | 0.090 |
Why?
|
| Plasma Exchange | 1 | 2011 | 24 | 0.090 |
Why?
|
| Contrast Media | 2 | 2012 | 429 | 0.080 |
Why?
|
| Acute Disease | 5 | 2017 | 672 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 903 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2011 | 117 | 0.080 |
Why?
|
| Infant, Low Birth Weight | 2 | 1994 | 61 | 0.080 |
Why?
|
| Alcoholism | 1 | 1993 | 328 | 0.080 |
Why?
|
| Metabolic Syndrome | 1 | 2011 | 147 | 0.080 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2010 | 59 | 0.080 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2010 | 96 | 0.080 |
Why?
|
| Parenteral Nutrition, Total | 1 | 1989 | 28 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2012 | 299 | 0.080 |
Why?
|
| Anaphylaxis | 2 | 2012 | 41 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2011 | 190 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 663 | 0.070 |
Why?
|
| Energy Metabolism | 1 | 2012 | 395 | 0.070 |
Why?
|
| Double-Blind Method | 4 | 2009 | 742 | 0.070 |
Why?
|
| Calcium | 3 | 2007 | 585 | 0.070 |
Why?
|
| Drug Therapy, Combination | 4 | 2011 | 464 | 0.070 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 35 | 0.070 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 3 | 1997 | 4 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 23 | 0.070 |
Why?
|
| Tetrazoles | 2 | 2005 | 22 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2008 | 49 | 0.070 |
Why?
|
| Biphenyl Compounds | 2 | 2005 | 30 | 0.070 |
Why?
|
| Term Birth | 1 | 2007 | 6 | 0.070 |
Why?
|
| Incidence | 3 | 2017 | 1404 | 0.070 |
Why?
|
| Length of Stay | 1 | 2011 | 823 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2008 | 92 | 0.070 |
Why?
|
| Renal Insufficiency | 2 | 2005 | 68 | 0.070 |
Why?
|
| Urban Population | 1 | 2008 | 201 | 0.060 |
Why?
|
| Nephrocalcinosis | 3 | 2007 | 5 | 0.060 |
Why?
|
| Hemostatic Techniques | 1 | 2006 | 12 | 0.060 |
Why?
|
| Surgical Instruments | 1 | 2006 | 44 | 0.060 |
Why?
|
| Acecainide | 1 | 1986 | 1 | 0.060 |
Why?
|
| Hemoperfusion | 1 | 1986 | 1 | 0.060 |
Why?
|
| Procainamide | 1 | 1986 | 6 | 0.060 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2006 | 47 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 1986 | 8 | 0.060 |
Why?
|
| Hyponatremia | 1 | 1986 | 11 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 308 | 0.060 |
Why?
|
| Proteins | 1 | 1992 | 764 | 0.060 |
Why?
|
| Peritonitis | 2 | 1997 | 43 | 0.060 |
Why?
|
| Bronchial Spasm | 1 | 1985 | 8 | 0.060 |
Why?
|
| Massachusetts | 2 | 2010 | 2142 | 0.060 |
Why?
|
| Metals, Heavy | 1 | 2005 | 8 | 0.060 |
Why?
|
| Lactates | 1 | 1985 | 29 | 0.060 |
Why?
|
| Lithium | 1 | 2005 | 21 | 0.060 |
Why?
|
| Urologic Diseases | 1 | 2005 | 18 | 0.060 |
Why?
|
| Lipids | 1 | 1988 | 328 | 0.060 |
Why?
|
| Iothalamic Acid | 3 | 2000 | 3 | 0.060 |
Why?
|
| Urinalysis | 2 | 2007 | 37 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2008 | 269 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2006 | 118 | 0.060 |
Why?
|
| Algorithms | 2 | 2020 | 1046 | 0.060 |
Why?
|
| Analgesics | 1 | 2005 | 103 | 0.050 |
Why?
|
| Logistic Models | 1 | 2008 | 1272 | 0.050 |
Why?
|
| Magnesium | 1 | 1985 | 55 | 0.050 |
Why?
|
| Cardiac Catheterization | 1 | 2006 | 292 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 21 | 0.050 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 23 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 62 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2011 | 469 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 130 | 0.050 |
Why?
|
| Cardioplegic Solutions | 1 | 2003 | 9 | 0.050 |
Why?
|
| Heart Arrest, Induced | 1 | 2003 | 13 | 0.050 |
Why?
|
| Obesity | 1 | 2011 | 1267 | 0.050 |
Why?
|
| Intraoperative Care | 1 | 2003 | 38 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2004 | 178 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2003 | 58 | 0.050 |
Why?
|
| United States | 4 | 2020 | 8048 | 0.050 |
Why?
|
| Cyclosporine | 2 | 2000 | 77 | 0.050 |
Why?
|
| Homeostasis | 1 | 1985 | 379 | 0.050 |
Why?
|
| Program Evaluation | 2 | 2017 | 493 | 0.050 |
Why?
|
| Equipment Design | 3 | 2010 | 361 | 0.040 |
Why?
|
| Infant, Newborn | 5 | 2007 | 1416 | 0.040 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2001 | 1 | 0.040 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2001 | 20 | 0.040 |
Why?
|
| Simplified Acute Physiology Score | 1 | 2020 | 1 | 0.040 |
Why?
|
| APACHE | 1 | 2020 | 43 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 955 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2005 | 364 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2000 | 39 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2000 | 130 | 0.040 |
Why?
|
| Cadaver | 1 | 2000 | 127 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 127 | 0.040 |
Why?
|
| Bicarbonates | 1 | 1998 | 17 | 0.040 |
Why?
|
| Aerosols | 1 | 1998 | 46 | 0.040 |
Why?
|
| Biopsy | 1 | 2000 | 455 | 0.040 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 1998 | 45 | 0.030 |
Why?
|
| Graft Rejection | 1 | 2000 | 302 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2011 | 735 | 0.030 |
Why?
|
| Computational Biology | 1 | 2020 | 367 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 164 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 1998 | 160 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2004 | 921 | 0.030 |
Why?
|
| Glucose | 2 | 2012 | 477 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 1998 | 212 | 0.030 |
Why?
|
| Graft Survival | 1 | 1999 | 298 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 295 | 0.030 |
Why?
|
| Renin | 1 | 1997 | 10 | 0.030 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 1997 | 7 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1164 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 36 | 0.030 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1997 | 16 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1997 | 159 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2020 | 383 | 0.030 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 28 | 0.030 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1997 | 40 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1997 | 49 | 0.030 |
Why?
|
| Hernia, Diaphragmatic | 1 | 1996 | 3 | 0.030 |
Why?
|
| Amino Acids | 2 | 1989 | 149 | 0.030 |
Why?
|
| Arteriovenous Fistula | 2 | 2006 | 42 | 0.030 |
Why?
|
| Chronic Disease | 3 | 2011 | 751 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1780 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 670 | 0.030 |
Why?
|
| Heart Rate | 1 | 1997 | 330 | 0.030 |
Why?
|
| Polycythemia | 1 | 1995 | 5 | 0.030 |
Why?
|
| Echocardiography | 1 | 1998 | 510 | 0.030 |
Why?
|
| Infant Food | 1 | 1994 | 3 | 0.030 |
Why?
|
| Vancomycin | 1 | 1995 | 39 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1995 | 30 | 0.030 |
Why?
|
| Albuminuria | 1 | 1995 | 30 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 850 | 0.030 |
Why?
|
| Blood Glucose | 1 | 1997 | 495 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 2605 | 0.030 |
Why?
|
| Ultrasonography | 2 | 1999 | 490 | 0.030 |
Why?
|
| Acid-Base Equilibrium | 1 | 1993 | 7 | 0.030 |
Why?
|
| Ketosis | 1 | 1993 | 3 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 1994 | 195 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 91 | 0.030 |
Why?
|
| Gestational Age | 2 | 2009 | 195 | 0.020 |
Why?
|
| Insulin | 1 | 1997 | 693 | 0.020 |
Why?
|
| Recurrence | 3 | 2001 | 660 | 0.020 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 66 | 0.020 |
Why?
|
| Basal Metabolism | 1 | 2012 | 23 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2005 | 525 | 0.020 |
Why?
|
| Breast Feeding | 1 | 1994 | 161 | 0.020 |
Why?
|
| Urea | 1 | 1992 | 41 | 0.020 |
Why?
|
| Body Composition | 1 | 2012 | 153 | 0.020 |
Why?
|
| Tomography, X-Ray | 1 | 1991 | 4 | 0.020 |
Why?
|
| Kidney Medulla | 1 | 1991 | 7 | 0.020 |
Why?
|
| Urography | 1 | 1991 | 13 | 0.020 |
Why?
|
| Aspirin, Dipyridamole Drug Combination | 1 | 2011 | 3 | 0.020 |
Why?
|
| Energy Intake | 1 | 2012 | 173 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 752 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4777 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2011 | 167 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 992 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 2010 | 36 | 0.020 |
Why?
|
| Parenteral Nutrition Solutions | 1 | 1989 | 4 | 0.020 |
Why?
|
| Pregnancy | 1 | 1997 | 2364 | 0.020 |
Why?
|
| Solutions | 1 | 1989 | 64 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 415 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2010 | 88 | 0.020 |
Why?
|
| Nephrons | 1 | 2009 | 7 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2009 | 23 | 0.020 |
Why?
|
| Epithelium | 1 | 2009 | 100 | 0.020 |
Why?
|
| Organogenesis | 1 | 2009 | 41 | 0.020 |
Why?
|
| Delayed-Action Preparations | 1 | 2009 | 118 | 0.020 |
Why?
|
| Ureter | 1 | 2009 | 37 | 0.020 |
Why?
|
| Morphogenesis | 1 | 2009 | 120 | 0.020 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1988 | 5 | 0.020 |
Why?
|
| Uremia | 1 | 1988 | 9 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 735 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2012 | 885 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 1663 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 419 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2010 | 317 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2006 | 1312 | 0.020 |
Why?
|
| Renal Veins | 1 | 1987 | 8 | 0.020 |
Why?
|
| Lipoma | 1 | 1987 | 17 | 0.020 |
Why?
|
| Renal Artery | 1 | 1987 | 36 | 0.020 |
Why?
|
| Hemangioma | 1 | 1987 | 28 | 0.020 |
Why?
|
| Femoral Vein | 1 | 2006 | 19 | 0.020 |
Why?
|
| Collateral Circulation | 1 | 2006 | 28 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2006 | 25 | 0.020 |
Why?
|
| Alloys | 1 | 2006 | 31 | 0.020 |
Why?
|
| Hemostasis | 1 | 2006 | 19 | 0.020 |
Why?
|
| Diuresis | 1 | 1986 | 6 | 0.020 |
Why?
|
| Water-Electrolyte Balance | 1 | 1986 | 15 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 67 | 0.020 |
Why?
|
| Arginine Vasopressin | 1 | 1986 | 22 | 0.020 |
Why?
|
| Saphenous Vein | 1 | 2006 | 51 | 0.020 |
Why?
|
| Aneurysm, False | 1 | 2006 | 47 | 0.020 |
Why?
|
| Hematoma | 1 | 2006 | 82 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2006 | 104 | 0.010 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 113 | 0.010 |
Why?
|
| Amlodipine | 1 | 2005 | 2 | 0.010 |
Why?
|
| Fanconi Syndrome | 1 | 1985 | 1 | 0.010 |
Why?
|
| Glycosuria | 1 | 1985 | 3 | 0.010 |
Why?
|
| Natriuresis | 1 | 1985 | 7 | 0.010 |
Why?
|
| Kidney Neoplasms | 1 | 1987 | 174 | 0.010 |
Why?
|
| Edetic Acid | 1 | 1984 | 24 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1984 | 10 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1985 | 81 | 0.010 |
Why?
|
| Kinetics | 1 | 1986 | 762 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1985 | 253 | 0.010 |
Why?
|
| Hypoxia | 1 | 1985 | 120 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 2003 | 5 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 2003 | 14 | 0.010 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2003 | 29 | 0.010 |
Why?
|
| Oxygen | 1 | 1985 | 323 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2003 | 90 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 1694 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 1106 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2001 | 18 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2003 | 224 | 0.010 |
Why?
|
| Muromonab-CD3 | 1 | 2000 | 7 | 0.010 |
Why?
|
| Azathioprine | 1 | 2000 | 28 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1999 | 106 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2000 | 249 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 215 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1999 | 49 | 0.010 |
Why?
|
| Creatine | 1 | 1999 | 23 | 0.010 |
Why?
|
| Sodium | 1 | 1997 | 62 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 856 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1996 | 40 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1997 | 209 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1997 | 609 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1995 | 57 | 0.010 |
Why?
|
| Calcium Phosphates | 1 | 1994 | 8 | 0.010 |
Why?
|
| Erythropoietin | 1 | 1995 | 38 | 0.010 |
Why?
|
| Family | 1 | 1996 | 245 | 0.010 |
Why?
|
| Decision Making | 1 | 1996 | 416 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1996 | 812 | 0.000 |
Why?
|
| Hematuria | 1 | 1987 | 23 | 0.000 |
Why?
|
| Acetic Acid | 1 | 1985 | 10 | 0.000 |
Why?
|
| Radiography | 1 | 1987 | 556 | 0.000 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1985 | 43 | 0.000 |
Why?
|
| Acetates | 1 | 1985 | 32 | 0.000 |
Why?
|
| Occupational Diseases | 1 | 1984 | 266 | 0.000 |
Why?
|